Travere Therapeutics officer proposes $101K sale
The proposed transaction is described as a required sell-to-cover sale for tax withholding, rather than a discretionary trade.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Travere Therapeutics, Inc. officer Elizabeth E. Reed reported a proposed sale of 2,174 common shares, with an aggregate market value of $101,417.10 and an approximate sale date of May 5, 2026. The shares were acquired from the issuer on May 4, 2026 through performance restricted stock unit vesting as compensation. The sale is required to cover tax withholding on the vested units under the issuer’s equity incentive plans; it is described as not discretionary.
Key Figures
Key Terms
Performance Restricted Stock Unit Vesting financial
sell to cover financial
tax withholding obligation financial
equity incentive plans financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.